Abstract
1 Kinetics of brotizolam (0.25 mg) were studied in patients with different degrees of renal failure after single and repeated oral ingestion. Serum levels were analysed by radio-immunoassay.
2 Patients were divided into three groups according to their renal function, i.e. creatinine clearance values of 45-80, 15-45, or less than 15 ml/min.
3 The mean elimination half-life was 6.9-8.15 h, with a considerable variation of the peak concentration and elimination half-life in slight to moderate renal failure. There was no delay in elimination in severe renal failure and there was no drug accumulation.
4 No dose adjustment is necessary for brotizolam in renal failure.
Keywords: brotizolam, pharmacokinetics, renal failure
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bechtel W. D. Pharmacokinetics and metabolism of brotizolam in humans. Br J Clin Pharmacol. 1983;16 (Suppl 2):279S–283S. doi: 10.1111/j.1365-2125.1983.tb02301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bennett W. M., Muther R. S., Parker R. A., Feig P., Morrison G., Golper T. A., Singer I. Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Ann Intern Med. 1980 Aug;93(2):286–325. doi: 10.7326/0003-4819-111-3-286. [DOI] [PubMed] [Google Scholar]
- Breimer D. D., Jochemsen R. Clinical pharmacokinetics of hypnotic benzodiazepines: a summary. Br J Clin Pharmacol. 1983;16 (Suppl 2):277S–278S. doi: 10.1111/j.1365-2125.1983.tb02300.x. [DOI] [PMC free article] [PubMed] [Google Scholar]